Disease: Waldenstrom macroglobulinemia
- 18 F-FDG PET/CT Findings in Waldenstrom Macroglobulinemia With Mesentery Involvement
- A 74-Year-Old Man With Waldenstrom Macroglobulinemia and Progressive Dyspnea
- A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia
- A phase II study of ibrutinib in combination with ixazomib in patients with Waldenstrom macroglobulinaemia
- A prospective clinical trial of TCD-induced regimen for symptomatic Waldenstrom macroglobulinemia
- A Rare Case of Non-IgM Lymphoplasmacytic Lymphoma with Unusual Lack of Immunoglobulin Light Chain Production
- A rare case of secondary cutaneous lymphoplasmacytic lymphoma clinically presenting as acquired cutis laxa
- A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS
- Advances in Treatment of Waldenstrom Macroglobulinemia
- An advanced case of Waldenstrom's macroglobulinemia complicated by acquired hemophilia a in a patient with neurofibromatosis type 1
- An unusual presentation of lymphoplasmacytic lymphoma with isolated brachial plexus infiltration and amyloidosis
- Asymptomatic erythematous plaques on the trunk
- Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer
- Bing-Neel syndrome: a rare neurological complication of Waldenstrom macroglobulinaemia
- Biomarker analysis of the ASPEN study comparing zanubrutinib to ibrutinib in patients with Waldenstrom Macroglobulinemia
- Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstrom macroglobulinemia
- Broadening the horizon: potential applications of CAR-T cells beyond current indications
- Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenstrom Macroglobulinemia
- BTK Inhibitors in CLL : Second Generation Drugs and Beyond
- Challenging diagnosis of IgM multiple myeloma
- Circulating tumor cells in Waldenstrom macroglobulinemia
- Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88<sup>L265P</sup> and CXCR4 mutations and underlying haemopathy
- Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia Associated With Diffuse Large B-cell Lymphoma
- Clonally related transformation from Waldenstrom macroglobulinemia to diffuse large B-cell lymphoma with central nervous system involvement at diagnosis: a case report and literature review
- Correction: Transformed Waldenström Macroglobulinemia Responsive to Tafasitamab Plus Lenalidomide: A Case Report
- Covalent docking-driven virtual screening of extensive small-molecule libraries against Bruton tyrosine kinase for the identification of highly selective and potent novel therapeutic candidates
- Cytogenetics in the management of mature B-cell non-Hodgkin lymphomas: Guidelines from the Groupe Francophone de Cytogénétique Hematologique (GFCH)
- Design and Rationale of Prolonged Nightly Fasting for Multiple Myeloma Prevention (PROFAST): Protocol for a Randomized Controlled Pilot Trial
- Diagnosis and treatment understanding of Waldenstrom macroglobulinemia in China: a cross-sectional study
- Diagnosis of Waldenstrom Macroglobulinemia Using Postoperative Histopathology During Routine Total Knee Arthroplasty: A Case Report
- Diffuse large B-cell lymphoma with continuously elevated immunoglobulin M following treatment: a case report with pathologic, immunophenotypic, and molecular analyses
- DLBCL arising from indolent lymphomas: How are they different?
- Dutcher bodies in a Waldenstrom Macroglobulinaemia patient
- Editor's Note: Eph-B2/Ephrin-B2 Interaction Plays a Major Role in the Adhesion and Proliferation of Waldenstrom's Macroglobulinemia
- Editor's Note: Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia
- Efficacy and safety of therapeutic procedure for Waldenstrom's macroglobulinemia with hyperviscosity syndrome
- Enhancing Plasmapheresis Efficacy in Waldenstrom Macroglobulinemia: Overcoming Circuit Clotting Challenges
- Erratum to: The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia
- Erratum: Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia
- Family Aggregation of Hematological Malignancies Discovered from an Acute Myeloid Leukemia Patient with STK11 and THBD Gene Mutation
- First in Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma
- First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma
- Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naive Waldenstrom macroglobulinemia in a real-world setting: a population-based a
- Gammopathic dermopathy: characterization of cutaneous MGUS
- Hematologic secondary malignancies among 102 Chinese patients with Waldenstrom's macroglobulinemia: a single-center case experience and literature review
- High efficacy of CD19 CAR T-cells in patients with transformed Waldenstrom macroglobulinemia
- How I use genomics and BTK inhibitors in the treatment of Waldenstrom macroglobulinemia
- How to manage waldenstrom's macroglobulinemia in 2024
- How we use Genomics and BTK-Inhibitors in the Treatment of Waldenstrom Macroglobulinemia
- Hyperviscosity Syndrome Induced Bilateral Visual and Auditory Impairment in Therapy Resistant Waldenstrom Macroglobulinemia with MYD88 and CXCR4 Mutations
- Ibrutinib (Imbruvica): CADTH Reimbursement Recommendation: Indication: Ibrutinib, with or without rituximab, for the treatment of adult patients with previously treated refractory or relapsed Waldenstrom's macroglobulinemia
- Ibrutinib and venetoclax as primary therapy in symptomatic treatment naïve Waldenström macroglobulinemia
- Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naive Waldenstrom macroglobulinemia
- Ibrutinib Efficacy, Safety, and Pharmacokinetics in Chinese Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia: A Multicenter, Single-Arm, Phase 4 Study
- Identification of robust predictors for ibrutinib response by multi-omics in MYD88 mutated Waldenstrom Macroglobulinemia
- Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study
- Impact of the presence and number of chromosomal abnormalities on the clinical outcome in Waldenstrom Macroglobulinemia: a monocentric experience
- In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation
- Indolent B-cell lymphoma with t(14;19) investigated from a molecular perspective
- Invasive fungal infection incidence and risk factors in patients receiving ibrutinib in real-life settings: A nationwide population-based cohort study
- Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrom macroglobulinaemia
- Long-term results of Waldenstrom macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO)
- Long-term Survival in a Patient With Transformation of Waldenstrom's Macroglobulinemia into DLBCL
- Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature review
- Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia Diagnosed Following Recurrent Epistaxis
- Mixed Diffuse and Tumoral Form of Bing-Neel Syndrome Successfully Treated with Ibrutinib
- Monoclonal gammopathy of renal significance: An atypical presentation of Waldenstrom's disease
- Mutational landscape in Waldenstrom macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice
- New developments in the diagnosis and characterization of Waldenstrom's macroglobulinemia
- Paraneoplastic Autoimmune Retinopathy Associated With Non-IgM Lymphoplasmacytic Lymphoma
- Paraproteinemic Keratopathy
- Paraproteinemic Neuropathies
- Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors
- PlentiPlex MYD88 Waldenstrom lymphoma qPCR assay: A highly sensitive method for detection of MYD88 L265P mutation
- Prevalence and clinical profiles of anti-myelin-associated glycoprotein neuropathy in Japan: A nationwide survey study of 133 patients
- Risk/benefit of BTK/venetoclax combos: the context matters!
- Rituximab plus cyclophosphamide and dexamethasone <em>versus</em> bortezomib plus cyclophosphamide and dexamethasone in newly diagnosed symptomatic Waldenström macroglobulinemia: a randomized controlled trial
- Rituximab plus cyclophosphamide and dexamethasone versus bortezomib plus cyclophosphamide and dexamethasone in newly diagnosed symptomatic Waldenstrom macroglobulinemia: a randomized controlled trial
- Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia
- Serum CXCL13 level is related to treatment response and predicts disease prognosis in Waldenstrom macroglobulinemia
- Single-cell analysis of MYD88(L265P) and MYD88(WT) Waldenstrom macroglobulinemia patients
- ST2825, independent of MyD88, induces reactive oxygen species-dependent apoptosis in multiple myeloma cells
- Teaching NeuroImage: Bing-Neel Syndrome Mimicking a Meningioma With a Frontal Subcutaneous Lesion
- The 503rd case: monoclonal IgM immunoglobulinemia, severe anemia with recurrent fever
- The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma
- The Expression Level and Diagnostic Value of Serum Free Light Chain in B-Cell Non-Hodgkin Lymphoma
- The performance and applied value of (18)F-FDG PET/CT imaging in Waldenstrom macroglobulinemia
- The performance and applied value of <sup>18</sup>F-FDG PET/CT imaging in Waldenstrom macroglobulinemia
- There's life in the old dog yet: immunochemotherapy in Waldenstrom's macroglobulinemia
- Uncovering the Challenges of Rare Diseases: Insights From a Retrospective Cross-Sectional Study in Albania (2005-2022)
- Use of Vonicog Alpha and Acquired von Willebrand Syndrome, a New Approach: A Case Report
- Waldenstrom Disease in a Renal Transplant: a Case Report and Review of the Literature
- Waldenstrom macroglobulinaemia with AA amyloidosis reveals a B-cell-restricted NLRP2 variant
- Waldenstrom Macroglobulinemia in Very Elderly (75-year-old) Patients: A 33-year-retrospective Cohort Study in an Italian University Hospital
- Waldenstrom Macroglobulinemia-Associated Peripheral Neuropathy in the Brachial Plexus With Bing-Neel Syndrome Diagnosed Through Repeated Cerebrospinal Tests
- Waldenstrom Macroglobulinemia: Targeted Agents Taking Center Stage
- Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
- Waldenstrom's Macroglobulinemia and Cryoglobulinemic Glomerulonephritis: An Unusual Case of Monoclonal Gammopathy of Renal Significance
- When Waldenstrom macroglobulinemia hits the kidney: Description of a case series and management of a "rare in rare" scenario
- Zanubrutinib in Waldenstrom Macroglobulinemia